Dashboard
Manage Tickers

NVRONEVRO CORP

NYSE nevro.com


$ 9.81 $ -0.15 (-1.51 %)    

Wednesday, 22-May-2024 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ -0.09 (-0.02 %)
DIA $ 398.57 $ -2.12 (-0.53 %)
SPY $ 530.36 $ -1.53 (-0.29 %)
TLT $ 91.26 $ 0.11 (0.12 %)
GLD $ 225.37 $ -4.12 (-1.84 %)
$ 9.81
$ 9.01
$ 0.00 x 0
$ 0.00 x 0
$ 8.93 - $ 9.99
$ 8.93 - $ 28.42
630,633
na
357.74M
$ 1.39
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 02-23-2024 12-31-2023 10-K
3 11-01-2023 09-30-2023 10-Q
4 08-01-2023 06-30-2023 10-Q
5 04-26-2023 03-31-2023 10-Q
6 02-21-2023 12-31-2022 10-K
7 11-02-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-23-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-04-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 02-24-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-05-2020 03-31-2020 10-Q
18 02-25-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 02-21-2019 12-31-2018 10-K
23 11-05-2018 09-30-2018 10-Q
24 08-02-2018 06-30-2018 10-Q
25 05-07-2018 03-31-2018 10-Q
26 02-22-2018 12-31-2017 10-K
27 11-06-2017 09-30-2017 10-Q
28 08-07-2017 06-30-2017 10-Q
29 05-08-2017 03-31-2017 10-Q
30 02-23-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-08-2016 06-30-2016 10-Q
33 05-09-2016 03-31-2016 10-Q
34 02-29-2016 12-31-2015 10-K
35 11-09-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-11-2015 03-31-2015 10-Q
38 03-18-2015 12-31-2014 10-K
39 12-02-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

citigroup-downgrades-nevro-to-sell-lowers-price-target-to-9
Citigroup Downgrades Nevro to Sell, Lowers...
05/22/2024 12:51:02

Citigroup analyst Joanne Wuensch downgrades Nevro (NYSE:NVRO) from Neutral to Sell and lowers the price target from $13.5 to...

assessing-nevro-insights-from-9-financial-analysts
Assessing Nevro: Insights From 9 Financial...
05/08/2024 21:00:28

canaccord-genuity-maintains-hold-on-nevro-lowers-price-target-to-11
Canaccord Genuity Maintains Hold on Nevro,...
05/08/2024 16:50:53

Canaccord Genuity analyst William Plovanic maintains Nevro (NYSE:NVRO) with a Hold and lowers the price target from $17 to $11.

wells-fargo-maintains-equal-weight-on-nevro-lowers-price-target-to-13
Wells Fargo Maintains Equal-Weight on Nevr...
05/08/2024 14:42:01

Wells Fargo analyst Nathan Treybeck maintains Nevro (NYSE:NVRO) with a Equal-Weight and lowers the price target from $14 to ...

piper-sandler-maintains-underweight-on-nevro-lowers-price-target-to-12
Piper Sandler Maintains Underweight on Nev...
05/08/2024 12:18:16

Piper Sandler analyst Adam Maeder maintains Nevro (NYSE:NVRO) with a Underweight and lowers the price target from $15 to $12.

nevro-reaffirms-fy24-revenue-guidance-of-435m-445m-est-441038m-sees-q2-revenue-of-106m-108m-est-111244m
Nevro Reaffirms FY24 Revenue Guidance Of $...
05/07/2024 21:46:30

Nevro is raising its adjusted EBITDA guidance for the full-year 2024 to a range of negative $5 million to positive $2 million f...

nevro-q1-2024-gaap-eps-070-beats-108-estimate-sales-101899m-beat-97892m-estimate
Nevro Q1 2024 GAAP EPS $(0.70) Beats $(1.0...
05/07/2024 20:59:19

Nevro (NYSE:NVRO) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(1.08) by 35.19 ...

rbc-capital-maintains-sector-perform-on-nevro-lowers-price-target-to-16
RBC Capital Maintains Sector Perform on Ne...
04/15/2024 18:21:39

RBC Capital analyst Shagun Singh maintains Nevro (NYSE:NVRO) with a Sector Perform and lowers the price target from $18 to $16.

mizuho-maintains-neutral-on-nevro-lowers-price-target-to-16
Mizuho Maintains Neutral on Nevro, Lowers ...
04/11/2024 11:38:47

Mizuho analyst Anthony Petrone maintains Nevro (NYSE:NVRO) with a Neutral and lowers the price target from $20 to $16.

wells-fargo-maintains-equal-weight-on-nevro-lowers-price-target-to-14
Wells Fargo Maintains Equal-Weight on Nevr...
04/08/2024 12:37:12

Wells Fargo analyst Larry Biegelsen maintains Nevro (NYSE:NVRO) with a Equal-Weight and lowers the price target from $17 to ...

where-nevro-stands-with-analysts
Where Nevro Stands With Analysts
04/03/2024 17:01:14

citigroup-maintains-neutral-on-nevro-lowers-price-target-to-16
Citigroup Maintains Neutral on Nevro, Lowe...
04/03/2024 15:56:58

Citigroup analyst Joanne Wuensch maintains Nevro (NYSE:NVRO) with a Neutral and lowers the price target from $18 to $16.

nevro-receives-fda-510k-clearance-to-use-si-fixation-system-without-need-to-include-lateral-screw
Nevro Receives FDA 510(k) Clearance To Use...
02/28/2024 21:54:13

Nevro1™ Proven to Immediately Transfix Sacroiliac (SI) Joint to Allow for Long-term SI Joint FusionREDWOOD CITY, Calif., Feb. 2...

analyst-scoreboard-4-ratings-for-nevro
Analyst Scoreboard: 4 Ratings For Nevro
02/22/2024 14:00:47

nevro-expects-worldwide-revenue-of-435m-445m-for-full-year-2024-est-44454m-97m-99m-for-q1-est-9872m
Nevro Expects Worldwide Revenue Of $435M-$...
02/21/2024 22:15:38

nevro-enters-cooperation-agreement-with-engaged-capital-appoints-kirt-p-karros-to-board
Nevro Enters Cooperation Agreement With En...
02/21/2024 21:58:29

nevro-q4-2023-gaap-eps-025-beats-049-estimate-sales-11618m-beat-11248m-estimate
Nevro Q4 2023 GAAP EPS $(0.25) Beats $(0.4...
02/21/2024 21:30:55

Nevro (NYSE:NVRO) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.49) by 48.98 ...

nevro-q4-earnings-insights
Nevro: Q4 Earnings Insights
02/21/2024 21:30:13

earnings-scheduled-for-february-21-2024
Earnings Scheduled For February 21, 2024
02/21/2024 10:09:04

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on...

nevro-announces-coverage-update-from-carelon-healthcare-for-the-treatment-of-painful-diabetic-neuropathy
Nevro Announces Coverage Update From Carel...
01/18/2024 21:19:22

Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the trea...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION